9 Results for "

VDAC2

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "VDAC2" in MCE Product Catalog:

935
935 Cited Publications
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation [2] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-128777
CAS No.: 2595314-46-6
Purity:  99.46%
Target:  

VDAC Apoptosis

Research Areas:  

Cancer

WEHI-9625 is a tricyclic sulfone, first-in-class inhibitor of apoptosis with an EC50 of 69 nM. WEHI-9625 binds to VDAC2 and promotes its ability to inhibit apoptosis driven by mouse BAK. WEHI-9625 is completely inactive against both human BAK and the closely related apoptosis effector BAX .
loading...
    loading...
Cat. No.: HY-172262
Research Areas:  

Cancer

WEHI-3773 is a VDAC2 ligand and apoptosis modulator. WEHI-3773 directly binds to the β7-β10 region of VDAC2 and disrupts its interaction with BAX and BAK. WEHI-3773 regulates BAX-mediated apoptosis in BAK-deficient cells by modulating conformational activation of BAX, mitochondrial redistribution, and cytochrome c release. WEHI-3773 overcomes Venetoclax (HY-15531) resistance, resensitizes leukemia cells carrying BAX mutations to BH3 mimetics, and enables long-term clonogenic survival of BAK-deficient cells treated with BH3 mimetics. WEHI-3773 is applicable to research related to acute myeloid leukemia [2].
loading...
    loading...
Cat. No.: HY-RS15630
Research Areas:  

Others

VDAC2 Human Pre-designed siRNA Set A contains three designed siRNAs for VDAC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS17560
Research Areas:  

Others

Vdac2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vdac2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS24018
Research Areas:  

Others

Vdac2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Vdac2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P706341
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Non-selective voltage-gated ion channel VDAC2; VDAC-2; mVDAC2; Outer mitochondrial membrane protein porin 2; Voltage-dependent anion-selective channel protein 6; VDAC-6; mVDAC6; VDAC2; VDAC6
Species:  
Mouse
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-15763R
CAS No.: 571203-78-6
Erastin (Standard) is the analytical standard of Erastin (HY-15763). This product is intended for research and analytical applications. Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation [2] .
loading...
    loading...
Cat. No.: HY-181529
CAS No.: 1212623-02-3
Target:  

VDAC PERK

Research Areas:  

Cancer

NCATS-SM0225 is an endoplasmic reticulum-associated degradation (ERAD) inhibitor and a direct binder of VDAC1, VDAC2 and VDAC3. NCATS-SM0225 exhibits an IC50of 1.02 μM for ERAD and a Kd of 3.13 μM for human VDAC1 binding. NCATS-SM0225 disrupts cellular calcium homeostasis, enhances VDAC1-IP3R coupling and activating PERK. NCATS-SM0225 selectively kills cancer cells, exhibits tumor growth inhibitory effects in melanoma xenograft models. NCATS-SM0225 can be used for research on multiple cancers including melanoma, as well as the molecular mechanisms of ERAD and calcium homeostasis regulation .
loading...
    loading...